Ultrahuman and Click Therapeutics Launch Biomarker-Driven Migraine PowerPlug

Ultrahuman has announced a partnership with Click Therapeutics to introduce the Migraine PowerPlug, a new digital tool designed to support people living with episodic migraine through biomarker-based insights and behavioral interventions. The PowerPlug integrates the proprietary technology underlying Click Therapeutics’ CT-132, which is FDA-authorized for the preventive treatment of episodic migraine, directly into the Ultrahuman platform.

Migraine is a chronic neurological condition affecting an estimated one billion people globally and is associated with significant disability and reduced quality of life. Rather than relying solely on symptom logging or retrospective tracking, the Migraine PowerPlug has been developed to help users identify physiological patterns that may precede or exacerbate migraine episodes and to respond to those patterns with structured guidance.

The tool continuously analyzes multiple biometric signals captured through Ultrahuman’s wearable ecosystem, including sleep metrics, recovery indicators, stress levels, and heart rate variability. By evaluating trends across these data streams, the platform aims to highlight individualized patterns that may be associated with increased migraine risk. When notable biometric shifts are detected, the PowerPlug translates those insights into personalized recommendations, such as daily movement goals, hydration targets, and sleep optimization guidance.

A distinguishing element of the PowerPlug is its use of digital therapeutics principles. Drawing on Click Therapeutics’ clinical expertise, the tool incorporates guided behavioral interventions intended to help users manage potential migraine triggers. These interventions are designed to be delivered at relevant moments, aligning behavioral support with real-time physiological changes rather than static advice.

Women’s health considerations are a central focus of the launch. Migraine is the leading cause of disability among women aged 15 to 49, and hormonal fluctuations are known to influence migraine frequency and severity for many patients. Building on Ultrahuman’s recent expansion into hormonal health technologies, the PowerPlug is intended to help users better understand how hormonal changes may intersect with their individual migraine patterns, offering a more integrated view of neurological and reproductive health.

“Helping people improve how they feel daily is core to Ultrahuman’s mission. By integrating the underlying principles of Click Therapeutics’ digital migraine treatment technology into our latest PowerPlug, we are enabling users to track and understand migraine-related patterns in real time, and then go further to turn those insights into actionable guidance,” said Mohit Kumar, CEO of Ultrahuman.

The Migraine PowerPlug is expected to become available through the Ultrahuman app in early 2026 following a pilot phase. Initial rollout is planned for the United States, Canada, the European Union, India, and Australia.

Click here for the original news story.